A Phase 4 interventional study of Atorvastatin and Placebo in Atherosclerosis, Melanoma and Immune-related Adverse Event, sponsored by Erasmus Medical Center. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-22.
Sponsored by Erasmus Medical Center · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing atorvastatin in Atherosclerosis — 1 open to participants now, 1 under way, none of them phase 3. Atorvastatin · Atherosclerosis.
Among the 24 studies testing atorvastatin in Atherosclerosis, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 10 in phase 4, and was the 24th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →1 of the 24 studies testing atorvastatin in Atherosclerosis is open now, in 1 country.
By country, each count listing its studies:
Atorvastatin: first FDA approval 1996 (LIPITOR). What it is approved for, and how studies give it, is on its page →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 6 · Phase 4 10
First in 2002; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is above the median of 100 across 881 interventional studies indexed under Atherosclerosis.
Median enrollment 52 across the 24 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 24 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing atorvastatin in Atherosclerosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06785974Erasmus Medical CenterStatins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies testing atorvastatin in Atherosclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this interventional study is to test whether atorvastatin prevents accelerated progression of atherosclerosis in melanoma patients who receive immune checkpoint inhibitor (ICI) therapy. The main questions it aims to answer are:
Researchers will compare patients that receive ICI-therapy and atorvastatin with patients that receive ICI-therapy + placebo to see if atorvastatin will prevent accelerated ICI induced plaque growth.
Rationale: Immune checkpoint inhibitors (ICIs) are often highly effective anti-cancer therapies but predispose patients receiving this treatment to cardiovascular disease and thrombotic events. One of the mechanisms by which ICIs increase cardiovascular risk is by stimulation of inflammation and atherosclerosis. Statins (e.g., atorvastatin) are frequently prescribed and effective anti-atherogenic agents, which could provide protective effects on the cardiovascular system in this patient population whilst and after receiving ICI, minimizing cardiovascular sequelae.
The objective of this study is to study if addition of atorvastatin prevents accelerated progression of atherosclerosis during ICI therapy. In addition, the investigators would like to study the effects of atorvastatin during ICI therapy on endothelial function, epicardial fat volume, and hemostatic and inflammatory parameters.
The main study endpoint is the difference in percentage growth of total atherosclerotic plaque volume in the descending thoracic segment of the aorta between intervention and control group, expressed in indexed percentage growth /year.
Secondary endpoints are differences in non-calcified and calcified plaque volume in the thoracic arteries and coronary arteries, epicardial fat volume, endothelial function, and quality of life. Exploratory endpoints include effect on hemostatic and inflammation markers, lipid levels, progression free survival, event free survival, and overall survival.
Trial design Placebo controlled prospective randomised controlled trial.
Trial population Melanoma patients who are scheduled to receive ICI therapy (nivolumab, pembrolizumab, or a combination of anti-PD1/ipilimumab; (neo)adjuvant, irresectable or metastasized melanoma) according to standard-of-care who are also eligible to initiate statin therapy.
The intervention group receives atorvastatin 20mg daily together with ICI therapy. The control group receives placebo together with ICI therapy.
Both groups will undergo two coronary and thoracic CT-scans. In addition, blood withdrawal will take place fourthly during the study. Furthermore, endothelial function will be assessed by means of the EndoPAT device at baseline and after one year of follow-up.
Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of patients represented by the trial subjects as well as the nature and extent of burden and risks: Patients in the intervention group will receive atorvastatin, of which safety and tolerability will be carefully monitored. Coronary atherosclerosis will be assessed via two coronary CT-scans, yielding a total limited extra radiation exposure of 4-10mSv. Blood withdrawal will be combined with regular blood withdrawal time points for standard care or will be withdrawn from the intravenous catheter for ICI administration. Vascular endothelial dysfunction will be assessed via Endothelial Peripheral Arterial Tonometry (EndoPAT) by recording finger arterial pulsatile volume change. This non-invasive method forms a minimal extra burden for participating patients. The investigators hypothesize that atorvastatin prevents accelerated progression of atherosclerosis and ameliorates ICI-induced vascular endothelial dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
for statin therapy, including:
Use of essential medication with (potential) interactions with atorvastatin, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient will receive 20mg of atorvastatin daily together with ICI-therapy
Drug: Atorvastatin
Patient will receive placebo daily together with ICI-therapy
Drug: Placebo
Daily 20mg atorvastatin.
Also known as: Lipitor, Atorvastatin Mylan
Daily Placebo in combination with ICI-therapy
Percentual annual growth of atherosclerotic plaques in the descending thoracic aorta
The percentage difference in atherosclerotic plaque volume in the descending part of the thoracic after 1 year of ICI-therapy will be compared to the atherosclerotic plaque volume at baseline.
Time frame: 1 year
Difference in percentage increase in non-calcified and calcified atherosclerotic plaque volume in the descending thoracic aorta
Difference in percentage increase in non-calcified and calcified atherosclerotic plaque volume in the descending thoracic aorta 1 year after the start of ICI therapy in the intervention versus the control group
Time frame: 1 year
Difference in percentage increase in total, non-calcified and calcified coronary artery atherosclerotic plaque volume
Difference in percentage increase in total, non-calcified and calcified coronary artery atherosclerotic plaque volume
Time frame: 1 year
Difference in increase in coronary calcification score (Agatston score) and Multi-Ethnic Study of Atherosclerosis (MESA) score
Difference in increase in coronary calcification score (Agatston score) and MESA score. MESA score calculates the 10-year risk in percentage of developing coronary heart disease.
Time frame: 1 year
Difference in change in epicardial fat volume
Difference in change in epicardial fat volume
Time frame: 1 year
Difference in reactive hyperaemia in-dex
Difference in reactive hyperaemia in-dex as a marker of endothelial dysfunc-tion using peripheral arterial tonometry (EndoPAT) between intervention and control group.
Time frame: 1 year
Difference in Quality of Life between intervention and control group using the FACT-M and EQ5D5L questionnaire.
Difference in QoL between intervention and control group using the FACT-M and the EQ5D5L questionnaires
Time frame: Baseline, 3 months, 6 months and 1 year after the start of ICI therapy
Differences in the number of adverse events
Differences in the number of adverse events between intervention and control group during the first year after start of ICI therapy, graded according to CTCAE criteria, version 5.0.
Time frame: 1 year
The effect of atorvastatin on median Progression Free Survival in months
The median progression free survival (PFS) in patients with advanced melanoma will be obtained after one and three years and will be calculated in months. Progression Free Survival (PFS) is defined as duration from randomization until disease progression.
Time frame: 1 and 3 years
The effect of statins on the median Overall Survival in months
The effect of statins on the median overall survival in months in patients with advanced disease after 1 and after 3 years. Overall Survival (OS) is defined as the duration from randomization until death from any cause
Time frame: 1 and 3 years
The effect of statins on the median Event Free Survival in months
The effect of statins on the median Event Free Survival in months in patients with advanced disease after 1 and after 3 years. Event Free Survival (EFS) is defined as the time from the start of the study treatment to the occurrence of progression to unresectable melanoma before surgery (in the neoadjuvant setting), disease recurrence, or death due to melanoma or due to treatment, whichever occurs first.
Time frame: 1 and 3 years
Difference in various concentration levels of hemostatic biomarkers
Difference in change in concentration levels of various markers of the hemostatic system activation (including d-dimer, fibrinogen, factor VIII, von Willebrand factor) between the intervention and control group at 3 months, 6 months, and 1 year after the start of ICIs.
Time frame: Baseline, 3 months, 6 months and 1 year after the start of ICI therapy
Difference in serum concentration of cardiovascular risk profile biomarkers
Difference in serum levels of the following parameters: HsCRP, VCAM, ICAM, TNF-α, IL-1β, IL-6, IL-10, Lipid profile, lp(a) between the intervention and control group at 3 months, 6 months and 1 year after the start of ICIs.
Time frame: Baseline, 3 months, 6 months and 1 year after the start of ICI therapy
Plan to share: Yes — The data will only become available after the study has been completed for at least 1 year. Only the IPD that have given informed consent to use the anonymous data will be available. After completion of the study, the Erasmus MC policy for requesting data will be applied. Furthermore, the General Data Protection Regulation must be complied with at all times.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: 2 years inclusion, 1 year after completion, 1 year analysis approximately 01-08-2028. Data will be available for 15 years after date of obtaining.
Access criteria: The data will only become available after the study has been completed for at least 1 year. After completion of the study, the Erasmus MC policy for requesting data will be applied. Furthermore, the General Data Protection Regulation must be complied with at all times.
Start is estimated for Feb 2025; primary completion for Feb 2027, 24 months later.
Of 45 non-industry phase 4 interventional studies under Atherosclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 24 months is below that.
Counting every sponsor, half of 55 studies reached it within 30 months; a quarter within 17 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin